http://www.fpnotebook.com/
Cognex
Aka: Cognex, Tacrine- See Also
- Indications
- Not considered first line due to hepatotoxicity
- Mild to Moderate Dementia (Folstein MMSE: 10-26)
- Mechanism
- First acetylcholinesterase inhibitor
- Other agents are now preferred
- Efficacy
- Response in 20% of patients
- Aricept offers similar efficacy and less toxicity
- Dosing
- Start at 10 mg PO qid for 4 weeks
- Increase to 20 mg PO qid for 4 weeks
- Titrate to maximum of 40 mg
- Adverse effects
- Hepatotoxicity
- Follow Liver Function Tests (esp. SGPT) every 2 weeks
- Hepatotoxicity
| Medication Costs | ||
|---|---|---|
| Cognex (on 2/9/2012 at DrugStore.com) | ||
| Cognex 10mg Capsules | #100 for $263.32 | ($2.63/unit) |
| Cognex 20mg Capsules | #100 for $263.32 | ($2.63/unit) |
| FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. | ||
Cognex (C0699954) |
|
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D013619 |
| English | cognex, Cognex, Horizon Brand of Tacrine Hydrochloride, OTL Pharm Brand of Tacrine Hydrochloride, Parke Davis Brand of Tacrine Hydrochloride |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Tacrine (C0039245) |
|
|---|---|
| Definition (MSH) | A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. |
| Definition (CSP) | cholinesterase inhibitor that crosses the blood-brain barrier; has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and to improve cognitive performance in the treatment of Alzheimer's disease and other central nervous system disorders. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D013619 |
| SnomedCT | 108494008, 373727000 |
| English | 1,2,3,4-Tetrahydroaminoacridine, 9-Amino-1,2,3,4-Tetrahydroacridine, Tetrahydroaminoacridine, 1,2,3,4-Tetrahydro-9-acridinamine, tetrahydroaminoacridine, 9-Acridinamine, 1,2,3,4-tetrahydro-, TACRINE, THA, tacrine (medication), tacrine, Tacrine [Chemical/Ingredient], tha, Tacrine (product), Tacrine (substance), Tacrine |
| Swedish | Takrin |
| Czech | takrin |
| Finnish | Takriini |
| Russian | TETRAGIDROAMINOAKRIDIN, TAKRIN, ТАКРИН, ТЕТРАГИДРОАМИНОАКРИДИН |
| Japanese | テトラハイドロアミノアクリジン, タクリン, テトラヒドロアミノアクリジン |
| Polish | Takryna |
| Spanish | tacrina (producto), tacrina (sustancia), tacrina, Tacrina, Tetrahidroaminoacridina |
| French | Tacrine |
| German | Tacrin, Tetrahydroaminoacridin |
| Italian | Tacrina |
| Portuguese | Tacrina, Tetraidroaminoacridina |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |